The evolving pharmacological landscape for pediatric and adult ADHD
The evolving pharmacological landscape for pediatric and adult ADHD
While attention-deficit/hyperactivity disorder (ADHD) medications, particularly stimulants, are among the most effective treatments in psychiatry, there remains a need for novel alternatives, as not all individuals with ADHD respond to or tolerate currently available medications. We aimed to provide an up-to-date overview of randomised controlled trials (RCTs) of agents either not approved for ADHD or approved for ADHD but tested for off-label indications. We updated, using the same methodology, two previous reviews (Cortese et al, 2023 exploring agents in the pipeline for children with ADHD, and Veronesi et al, 2024, focusing on RCTs of novel compounds in adults with ADHD). For the update, we searched ClinicalTrials.gov and the European Union-based EU Clinical Trials registers up to December 14, 2025. Including the RCTs retrieved by the two previous reviews and those from the updated search, we identified a total of 53 eligible RCTs. Of these, 11 reported results in children and adolescents, and 11 in adults. Considering agents with at least two positive trials for ADHD core symptoms without negative trials, only dasotraline, in children, and centanafadine, in adults, emerged as promising (however, the dasotraline development programme was halted in 2020). This review also includes a discussion of opportunities for advancing the development of novel, effective agents and maximising the benefits of currently available options.
901-920
Fusetto Veronesi, Guilherme
4af0a76e-8657-4b99-b174-027605ef63dc
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Pirolo, Daniele
c6f03ff1-f4e8-4869-b449-026d92831c8c
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
21 May 2026
Fusetto Veronesi, Guilherme
4af0a76e-8657-4b99-b174-027605ef63dc
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Pirolo, Daniele
c6f03ff1-f4e8-4869-b449-026d92831c8c
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Fusetto Veronesi, Guilherme, Tarantino, Fabio, Pirolo, Daniele and Cortese, Samuele
(2026)
The evolving pharmacological landscape for pediatric and adult ADHD.
CNS drugs, 40 (7), .
(doi:10.1007/s40263-026-01299-4).
Abstract
While attention-deficit/hyperactivity disorder (ADHD) medications, particularly stimulants, are among the most effective treatments in psychiatry, there remains a need for novel alternatives, as not all individuals with ADHD respond to or tolerate currently available medications. We aimed to provide an up-to-date overview of randomised controlled trials (RCTs) of agents either not approved for ADHD or approved for ADHD but tested for off-label indications. We updated, using the same methodology, two previous reviews (Cortese et al, 2023 exploring agents in the pipeline for children with ADHD, and Veronesi et al, 2024, focusing on RCTs of novel compounds in adults with ADHD). For the update, we searched ClinicalTrials.gov and the European Union-based EU Clinical Trials registers up to December 14, 2025. Including the RCTs retrieved by the two previous reviews and those from the updated search, we identified a total of 53 eligible RCTs. Of these, 11 reported results in children and adolescents, and 11 in adults. Considering agents with at least two positive trials for ADHD core symptoms without negative trials, only dasotraline, in children, and centanafadine, in adults, emerged as promising (however, the dasotraline development programme was halted in 2020). This review also includes a discussion of opportunities for advancing the development of novel, effective agents and maximising the benefits of currently available options.
Text
V2_clean
- Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy
Text
Table 1_resubmission_v2
- Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy
Text
Supplementary Information_v2
- Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy
More information
Accepted/In Press date: 20 April 2026
e-pub ahead of print date: 21 May 2026
Published date: 21 May 2026
Identifiers
Local EPrints ID: 512044
URI: https://eprints.soton.ac.uk/id/eprint/512044
ISSN: 1172-7047
PURE UUID: 8e08461f-94b5-4d51-bddb-2917242dacd3
Catalogue record
Date deposited: 15 Jun 2026 16:36
Last modified: 13 Sep 2026 15:48
Export record
Altmetrics
Contributors
Author:
Guilherme Fusetto Veronesi
Author:
Fabio Tarantino
Author:
Daniele Pirolo
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics